RESUMO
123I-metaiodobenzylguanidine (MIBG) and 111In-pentetrotide SPECT have been used for functional imaging of neuroendocrine tumors (NETs) for the last 2 decades. More recently, PET/CT imaging with 18F-FDG, 18F-fluorodihydroxyphenylalanine (FDOPA), and 68Ga somatostatin-receptor ligands in NETs has been expanding. A literature search could find no direct measurements of the dose rate from NET patients exiting the nuclear medicine department after undergoing PET/CT with 18F-FDOPA or 68Ga-DOTATOC, a somatostatin analog. Methods: We measured the dose rates from 93 NET patients on leaving the department after undergoing PET/CT or SPECT/CT in our centers. In total, 103 paired measurements of equivalent dose rate at 1 m (EDR-1m) from the sternum and urinary bladder were obtained. The detector faced the sternum or bladder and was 1 m away from and directly in front of the patient. The practice for exiting the department differed according to whether the patient had been referred for PET/CT or for SPECT/CT. PET/CT patients were discharged after imaging, whereas SPECT/CT patients left the department earlier, just after radiopharmaceutical injection. Results: The median administered activity was 122 MBq in 53 68Ga-DOTATOC PET/CT studies, 198 MBq in 15 18F-FDOPA PET/CT studies, and 176 MBq in 13 18F-FDG PET/CT studies. The corresponding median EDR-1m was 4.8, 9.5, and 8.8 µSv/h, respectively, facing the sternum, and 5.1, 10.1, and 9.5 µSv/h, respectively, facing the bladder. The median administered activity was 170 MBq in 12 111In-pentetreotide SPECT/CT studies and 186 MBq in 10 123I-MIBG SPECT/CT studies. The corresponding median EDR-1m was 9.4, and 4.9 µSv/h, respectively, at the level of the sternum, and 9.3 and 4.7 µSv/h, respectively, at the level of the bladder. The EDR-1m was less than 20 µSv/h in all patients. Thus, when exiting the nuclear medicine department, the NET patients injected with 68Ga-DOTATOC or 123I MIBG emitted an average EDR-1m roughly half that of patients injected with other radiopharmaceuticals. This finding is a complementary argument for replacing SPECT by PET somatostatin-receptor imaging. Conclusion: Our current practice of allowing patients to exit after PET/CT imaging or just after SPECT radiopharmaceutical injection appears to be safe from a radiation protection point of view. Restrictive advice is unnecessary for NET patients being discharged from the department.
Assuntos
Tumores Neuroendócrinos/diagnóstico por imagem , Medicina Nuclear , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Doses de Radiação , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radiometria , Compostos Radiofarmacêuticos , Fatores de TempoRESUMO
Differential and integral electron impact ionisation cross sections were calculated using the binary-encounter-Bethe theoretical model for each core particle molecules: the four DNA bases, the backbone (sugar phosphate), and the 19 amino acids constituent of histone proteins. The binding energies and populations of molecular orbitals were computed using General Atomic Molecular Electronic Structure System. At present, there are neither experimental nor other theoretical results on amino acid electron impact ionisation cross sections. Regarding DNA bases and backbone, our results show good agreement with those published in journals.